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Objective: Paclitaxel has one of the highest response rates when used as a single
agent in patients with esophageal cancer. The combination of paclitaxel and carbo-
platin has been shown to be a well-tolerated and safe regimen in non–small cell lung
cancer. The objective of this study was to determine the efficacy of preoperative
paclitaxel and carboplatin in patients with carcinoma of the esophagus.
Patients and Methods: A phase II trial was initiated in January 1999 and concluded
in January 2001. All patients had potentially resectable disease (including clinical
T4 lesions). Patients with stage I disease and those with visceral metastases were
excluded. All underwent preoperative computed tomography scanning and en-
dosonography for staging. Paclitaxel (200 mg/m2) and carboplatin (area under the
curve  6) were given on days 1 and 22. Esophagectomy was carried out on weeks
6 to 8.
Results: Twenty-six (11 epidermoid, 15 adenocarcinoma) patients completed the
trial. Median age was 61.5 and 85% were men. Preoperative staging showed: stage
IIA, 6 patients; stage IIB, 1 patient; and stage III, 19 patients. All patients completed
their preoperative chemotherapy. There was no unexpected chemotherapy-related
toxicity. A major clinical response was achieved in 16 patients (61%: 19% com-
plete, 42% partial). Resectability was 77% (20/26). A complete pathologic response
was seen in 11% of all patients and in 25% of those with epidermoid cancer.
Hospital mortality and morbidity were 4 and 27%, respectively. Overall 3-year
survival was 48% (64% for resected patients, median not reached). All 6 unresect-
able patients died within 6 months of exploration.
Conclusion: Paclitaxel-carboplatin combination is a safe and well-tolerated regimen
for esophageal cancer with clinical response rates comparable to historical controls.
This regimen may be especially suitable for patients with epidermoid cancer, who
had a 25% pathological complete response in this report.
Although esophagectomy remains the standard of care for esopha-geal cancer, the reported survival following conventional resec-tion techniques rarely exceeds 30%.1-8 We have previously re-ported our results after radical en bloc esophagectomy.9 The5-year overall and disease-free survival was 46 and 40%, respec-tively. Importantly, locoregional recurrence (defined as anasto-
motic recurrence or any recurrence within the operative field) occurred in fewer than
10% of patients. This low local failure rate compares favorably with that reported
after chemoradiation alone10 or that following preoperative chemoradiation.11
Therefore, we have elected not to include radiotherapy in our treatment strategies for
esophageal cancer. However, because more than 50% of patients eventually die due
to systemic disease, a reasonable argument could be made for including chemo-
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therapy in any treatment paradigm for this disease. Several
randomized trials have evaluated the merit of preoperative
chemotherapy compared with surgery alone.2-5 The chemo-
therapy regimen of choice in most trials of preoperative
chemotherapy was cisplatin and 5-fluorouracil. This regi-
men generally results in a clinical response rate of 50% to
70% and a complete pathological response in less than 5%
of patients.2,4
The microtubule interfering agent paclitaxel has demon-
strated significant activity in esophageal carcinoma, with a
32% response rate in patients with metastatic or locally
advanced disease.12,13 Carboplatin, an analog of cisplatin,
has activity similar to cisplatin in a number of tumor types,
and it provides several practical advantages over cisplatin.
First, nausea and vomiting related to carboplatin are sub-
stantially less than with cisplatin, which may be an advan-
tage in a population that is already nutritionally compro-
mised. Second, the relative lack of nephrotoxicity and
decreased need for hydration allows treatment in the outpa-
tient setting and decreases the likelihood of dose reductions
or delays due to nephrotoxicity. Finally, the combination of
paclitaxel and carboplatin has been extensively studied in a
variety of tumor types, and its toxicities are well established
and generally considered to be quite tolerable. For these
reasons, and encouraged by the ability of en bloc resection
to improve local disease control, we elected to examine the
efficacy of the combination of paclitaxel and carboplatin
given prior to en bloc esophagectomy.
Patients and Methods
From January 1999 to May 2001, 26 patients with histologically
confirmed squamous cell carcinoma or adenocarcinoma of the
esophagus were entered into this study. Patients were considered
eligible if they had disease limited to the esophagus and regional
lymph nodes. Preoperative evaluation included a complete history
and physical examination, routine laboratory evaluation, esopha-
gogastroduodenoscopy, endoscopic ultrasonography (EUS), bar-
ium swallow, and computed tomography (CT) scan of the chest
and upper abdomen. Patients were excluded if they had intramu-
cosal or submucosal tumors as determined by preoperative EUS.
Patients were also considered ineligible for the study if they
received prior chemotherapy or radiotherapy, had unstable cardio-
vascular disease, had a Karnofsky performance status of70%, or
had inadequate pulmonary, renal, hepatic, or hematologic function
to undergo chemotherapy and the subsequent planned operation.
The study design was reviewed and approved by the institutional
review board, and informed consent was obtained from all pa-
tients.
Treatment Plan
All patients received 2 cycles of paclitaxel and carboplatin 21 days
apart. Paclitaxel 200 mg/m2 was given as a 3-hour infusion,
followed by carboplatin dosed to an area under the curve of 6 by
the Calvert formula, given as a 1-hour infusion. All patients were
premedicated with dexamethasone 20 mg by mouth, given approx-
imately 7 and 12 hours before each dose of chemotherapy, and
with granisetron 0.7 mg intravenous (IV), dexamethasone 20 mg
IV, diphenhydramine 50 mg IV, and famotidine 20 mg IV, given
immediately before each dose of chemotherapy. Restaging evalu-
ation was carried out 2 to 3 weeks after the second cycle of
chemotherapy. Restaging included a CT scan of the chest and
upper abdomen and esophagogastroduodenoscopy. All patients
without evidence of systemic disease on posttreatment staging
underwent surgical exploration 6 to 8 weeks after the first course
of preoperative chemotherapy.
Response
A clinical complete response was defined as complete absence of
tumor on the CT scan and the absence of tumor on endoscopic
biopsy. A partial response was defined as a 50% reduction in tumor
length as determined by posttreatment contrast esophagogram or
esophagoscopy. A complete pathological response was defined as
the absence of any tumor in the esophagus and resected lymph
nodes.
Surgical Resection
All patients had an en bloc esophagectomy as previously de-
scribed.14 Briefly, the tumor-bearing esophagus was resected en
bloc within a wide envelope of adjacent tissues including both
pleural surfaces laterally, the pericardium anteriorly, and all lym-
phatic and areolar tissues wedged dorsally between the esophagus
and the spine. Additionally, the thoracic duct was resected en bloc
with the esophagus and a complete mediastinal and upper abdom-
inal lymphadenectomy was performed. Neither the azygous trunk
nor the intercostal vessels were included in the resection. Fifteen
patients also underwent dissection of the lymph nodes in the
superior mediastinum along both recurrent laryngeal nerves, as
well as a modified infraomohyoid cervical lymph node dissection
as previously described.15
Postoperative Therapy
Patients who had an objective clinical response or those with stable
disease received 2 postoperative cycles of the same preoperative
chemotherapy. No adjuvant radiotherapy was planned. Postoper-
ative treatment of incompletely resected patients or those with
unresectable or progressive disease was left to the discretion of the
treating physician.
Follow-up
Follow-up was complete in all patients until death or December
2002. Patients were seen in the thoracic oncology clinic every 3
months. Follow-up evaluation included physical examination, rou-
tine laboratory analysis, and chest radiography at each visit. A CT
scan of the chest and upper abdomen was performed at 6 months
and 12 months postoperatively, then yearly thereafter. Recurrence
was documented histologically in all cases. The median follow-up
was 22 months for all patients and 27 months for resected patients.
Statistics
Kaplan-Meier survival analysis was performed to estimate the
overall survival probabilities for all patients and separately for
resected patients. Ninety-five percent confidence intervals for all
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estimated survival probabilities were calculated to assess the pre-
cision of the estimates.
Results
Twenty-six patients were enrolled between January 1999
and January 2001. Patient characteristics are shown in Table
1. Median age was 61.5 years, and the majority of patients
were men (85%). Eleven patients (42%) had squamous cell
carcinoma and 15 (58%) had adenocarcinoma. Pretreatment
clinical stages were as follows: stage IIA, 6 patients (27%);
stage IIB, 1 patient (8%); stage III, 19 patients (65%).
Induction Therapy
All 26 patients completed both cycles of paclitaxel and
carboplatin preoperatively. One patient required dose reduc-
tion due to neutropenia with fever, but subsequently devel-
oped neutropenic fever after the second course of treatment
at a reduced dose. Grade 3 to 4 granulocytopenia occurred
in 6 cycles of chemotherapy (12%). Other toxicities, listed
in Table 2, were generally mild and easily treated.
Response to Therapy
Twenty-five of 26 patients (95%) reported a subjective
improvement in dysphagia within 1 week after the first
course of chemotherapy. Eleven patients (42%) had a partial
clinical response to chemotherapy and 5 (19%) had a com-
plete clinical response, as previously defined. One patient
had clinical progression of disease.
Surgical Treatment
One patient had disease progression as evidenced by liver
metastases detected on restaging CT scan and was taken off
study. Twenty-five patients underwent surgical exploration.
Surgical mortality and morbidity were 4 and 28%, respec-
tively (Table 3). Five patients with clinical T4 disease were
unresectable at thoracotomy due to direct airway invasion (n
 3) or aortic invasion (n 2). Esophagectomy was carried
out in 20 patients. Fifteen patients whose tumors were
located within the tubular esophagus underwent 3-field
lymph-node dissection, and 5 patients with tumors involv-
ing only the gastroesophageal junction underwent 2-field
lymph-node dissection. Eighteen patients had an R-O resec-
tion (69%); 1 patient had an R-1 resection (microscopic
residual disease at the esophageal margin); and 1 patient had
an R-2 resection due to intraoperatively detected previously
unsuspected liver metastases. Seven of 15 patients who had
a 3-field lymph node dissection were found to have occult
previously unsuspected metastases to the recurrent laryn-
geal lymph nodes, including the previously mentioned pa-
tient who also had unsuspected liver metastases. Three of 20
patients (11%) had a complete pathological response and all
had squamous histology. No patient with adenocarcinoma
had a complete pathologic response. Overall, 7 patients
were down-staged and 10 were up-staged including 6 pa-
tients found to have M1a disease based on recurrent laryn-
geal nodal metastases (Table 4).
TABLE 2. Preoperative chemotherapy toxicities (grades 3
to 4)
Toxicity Patients
Leukopenia 6 (12%)
Anemia 3 (6%)
Thrombocytopenia 1 (2%)
Myalgia/arthralgia 1 (2%)
Nausea/vomiting 0
Neuropathy 0
Neutropenic fever 2 (4%)
TABLE 3. Postoperative complications
Mortality (sepsis) 1 (4%)
Morbidity
Arrhythmia 4 (16%)
Anastomotic leak 2 (8%)
Respiratory failure 3 (12%)
Wound infection 1 (4%)
Pulmonary embolus 1 (4%)
Laryngeal nerve injury 1 (4%)
Gastrotracheal fistula 1 (4%)
Total 13 (7 patients, 28%)
TABLE 4. Treatment results
Pretreatment stage Posttreatment stage
T0 N0: 0 T0 N0: 3 (12%)
I: 0 I: 0
IIA: 6 (23%) IIA: 6 (23%)
IIB: 1 (3.8%) IIB: 1 (4%)
III: 19 (73%) III: 8 (31%)
IV: 0 IV: 7 (27%)
TABLE 1. Patient characteristics
Age range 36–77
Median age 61.5
Male/female 22/4
Race
White 20 (77%)
Asian 2 (8%)
Hispanic 4 (15%)
Cell type
Adenocarcinoma 15 (58%)
Squamous 11 (42%)
TNM stage
T3 N0 6
T2 N1 1
T3 N1 14
T4 Nx 2
T4 N1 3
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Survival
Overall actuarial 3-year survival was 48% (95% confidence
interval; 27%-68%) for all 26 patients based on an inten-
tion-to-treat analysis (Figure 1). All 5 patients with unre-
sectable disease died within 6 months of surgical explora-
tion. Overall actuarial 3-year survival for the 20 resected
patients was 64% (95% confidence interval, 39%-85%; me-
dian not reached; Figure 2). Three of the 7 patients with
positive recurrent laryngeal nodes are alive; 1 has recurrent
disease and 2 are disease-free.
Discussion
Though the potential benefits of preoperative chemotherapy
have been studied extensively, there has been no clear
demonstration of a survival benefit associated with that
approach, with the possible exception of those patients who
achieve a complete pathologic response.3,5 Unfortunately,
complete pathological response rates after the commonly
used regimen of 5-fluorouracil and cisplatin is only 3%.2
The addition of preoperative radiation to chemotherapy
results in higher response rates; however, a survival benefit
has not been demonstrated in most of the published ran-
domized trials that compared trimodality therapy with sur-
gery alone.6-8 Furthermore, the high local failure rate after
chemoradiation alone (34%) or after induction chemo-
therapy (39%) argues against regimens that add radiation
to chemotherapy and surgery. In contrast, the use of
preoperative chemotherapy may be ideally suited for the
treatment of a disease where more than 50% of relapse
occurs at distant sites.
The introduction of newer, more active chemotherapeu-
tic agents with improved therapeutic index invites further
evaluation of this treatment strategy. In particular, paclitaxel
has demonstrated high efficacy in esophageal cancer12,13
and, because of its favorable toxicity profile and synergy
with platinum derivatives, appears well suited for study in
the preoperative setting. Because pathologic complete re-
sponse seems to correlate with survival benefit, an improve-
ment in these parameters in a pilot trial would warrant
further investigation in a larger controlled trial.
In this trial we investigated the feasibility and efficacy of
taxane-based chemotherapy given alone before esophagec-
tomy. The data suggest the regimen is feasible and safe,
with a 4% treatment-related mortality. All but 1 patient
completed the preoperative therapy at the prescribed dose.
Chemotherapy-related complications were generally well
tolerated. The overall clinical response rate was 61% and
was comparable to that reported with other regimens. The
response rates reported herein are of particular interest as
patients with stage I disease were specifically excluded from
the study and 5 patients with clinical T-4 disease were
included, thus biasing the study population toward more
advanced stages. Nonetheless, relief of dysphagia was
Figure 1. Kaplan-Meier survival for all patients.
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promptly achieved in over 90% of patients, obviating the
need for parenteral or enteral nutritional support during
chemotherapy. The R-0 resection rate reported in this trial is
only 69%. If only patients with potentially resectable dis-
ease at enrollment are considered, the R-0 resection rate
would approach 90%. The overall resectability rate is based
on an intention-to-treat analysis including 6 patients with
clinical T-4 disease. One of these patients developed sys-
temic disease after induction chemotherapy, and the remain-
ing 5 patients were found unresectable at thoracotomy either
due to aortic (n  2) or major airway invasion (n  3). It is
possible that in this subgroup of patients, better response
rates may achievable after preoperative chemoradiation
compared with induction chemotherapy alone.
Finally, the complete pathological response rate was
11% for the whole group and 15% for those with resectable
disease. The complete pathological response rate was 25%
for patients with squamous cell carcinoma and suggests that
taxane-based chemotherapy may be particularly useful in
this subset of patients.
Despite these encouraging results, the findings in 15
patients who underwent 3-field lymph node dissection are
alarming. Nearly 50% of patients had unsuspected nodal
metastases to the recurrent laryngeal nodes and in 2 patients
that was the only site of nodal disease. Both had squamous
cell carcinoma, located in the upper third in the first patient
and the lower third in the other. The prevalence of nodal
disease in this potentially resectable group of patients sug-
gests either the need for extending the limit of nodal dis-
section after conventional esophagectomy or inclusion of
these areas in any planned pre- or postoperative radiation
port. Nonetheless, among 7 patients with metastases to the
recurrent laryngeal nodes, 2 (28%) are alive and free of
disease. Although the numbers are small, the 25% to 30%
5-year survival in patients with recurrent laryngeal nodal
disease is consistent with our previously reported results.15
In summary, this pilot trial demonstrates significant ac-
tivity and tolerable toxicity for the combination of carbo-
platin and paclitaxel in the preoperative treatment of esoph-
ageal cancer, with no impact on surgical morbidity and
mortality. These results should be confirmed in a larger
phase II trial.
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